Biblio
BEAM Vs BUCYVP16 CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH HODGKIN'S LYMPHOMA. Biol Blood Marrow Transplant. 2019.
Comparison of Two Doses of Antithymocyte Globulin in Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (allo HSCT). Biol Blood Marrow Transplant. 2019.
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse. Blood Adv. 2020;4(13):3102-3108.
. Lower Dose of Antithymocyte Globulin (ATG) does not increase Graft-vs-Host Disease (GVHD) in Patients Undergoing Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (allo HSCT). Leuk Lymphoma. 2014:1-20.
A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models. Exp Hematol Oncol. 2023;12(1):79.
Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia. Leuk Lymphoma. 2023:1-10.
Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma. Blood Adv. 2024.
PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia. Blood. 2021.
A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults. Blood. 2024.
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019;380(17):1628-1637.
Tocilizumab for steroid refractory acute graft-versus-host disease. Leuk Lymphoma. 2015:1-5.